The text starts here.

News Release

FOR IMMEDIATE RELEASE
March 5, 1997

Eisai's New Alzheimer's Disease Treatment Was Filed In Mexico By Wyeth-Ayerst

March 5, 1997 - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that Wyeth-Ayerst, a subsidiary of American Home Products Corporation, filed a new drug application with the Mexican Ministry of Health on January 17, 1997 for Eisai's new Alzheimer's disease treatment, donepezil hydrochloride or E2020 under the trademark of ERANZ(TM) in Mexico.


E2020 is a novel acetylcholinesterase inhibitor synthesized by Eisai in Japan, and is being developed by Eisai in Japan, Europe and in the US. Under the trademark of ARICEPT(TM), the compound was approved for marketing by the US Food and Drug Administration (FDA) in November 1996, and was also approved by the UK Medicines Control Agency (MCA) in February 1997. The compound is in the Phase III clinical trial stage in Japan.


In February 1995, Eisai Co., Ltd. concluded a license agreement with American Home Products Corporation for E2020, an Alzheimer's disease treatment in Latin America. Applications for registration in other major Latin American countries will be submitted later this year by Wyeth-Ayerst.


Wyeth-Ayerst, a subsidiary of American Home Products Corporation, is a major research-oriented pharmaceutical company with leading products in the areas of central nervous system drugs, women's health care, cardiovascular and metabolic disease therapies, anti-inflammatory agents, vaccines, infant nutritionals, and generic pharmaceuticals. American Home Products is one of the world's largest research-based pharmaceutical health care products companies and is a leading developer, manufacturer, and marketer of prescription drugs and over-the-counter medications. It is also a leader in vaccines, biotechnology, crop protection products, animal health care, and medical devices.


Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported sales of $2.6 billion in 1995 with approximately 14 percent of sales spent for research and development.